Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water

Journal of Toxicology - Clinical Toxicology

Volumn 36, Issue 7, 1998, Pages 683-690

  Guha Mazumder, Debendra N ^a   Ghoshal, Uday C ^a   Saha, Jayanta ^a   Santra, Amal ^a   De Binay, K ^a   Chatterjee, Amitabha ^b   Dutta, Subir ^b   Angle, Carol R ^c   Centeno, Jose A ^d  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CHELATING AGENT; DRINKING WATER; GROUND WATER; PLACEBO; SUCCIMER;

ADULT; ARTICLE; CHELATION THERAPY; CHRONIC TOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INDIA; INTOXICATION; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; TREATMENT OUTCOME; WATER CONTAMINATION;

ANIMALIA;

EID: 2142757595     PISSN: 07313810     EISSN: None     Source Type: Journal    
DOI: 10.3109/15563659809162616     Document Type: Article

References (26)

1. Chakraborty AK, Saha KC. Arsenical dermatosis from tubewell water in West Bengal. Indian J Med Res 1987;35:326-334.
2. Guha Mazumder DN, Das Gupta J, Santra A, et al. Chronic arsenic toxicity in West Bengal. The worst calamity in the world. J Ind Med Assoc 1998;96:4-7.
3. Borgono JM, Vicent P, Venturino H, Infante A. Arsenic in drinking water of the city of Antofagasta: Epidemiological and clinical study before and after installation of a treatment plant. Eviron Health Perspect 1977;19:103-105.
4. WHO, ECEH working group on health effects of arsenic in drinking water, (corresponding author: Carlos FC Dora). Human exposure and health effects of arsenic in drinking water in Hungary and Romania. Abstract SEGH 2nd Int Conf on As Exposure and Health Effects, San Diego, CA, June 1995:10.
5. Dhar RK, Biswas BK, Samanta G, et al. Groundwater arsenic calamity in Bangladesh. Current Science 1997;73:48-59.
6. Bencko V, Grotzl M, Rames J. Human arsenic exposure related skin Basalioma cancer epidemiology. Proc of Workshop: Arsenic: Health Effects, Mechanisms of Actions and Research Issues, organized by NCI, NIEHS and EPA, Hunt Valley, MD. Sept. 22-24, 1997, PS 20.
7. Tseng WP, Chu HM, How SW, et al. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 1968;40:453-463.
8. Arguello RA, Cenget DD, Tello. Cancer and endemic arsenic in the Cordoba Region. Rev Argent Dermatosifilog 1938;22:461-487.
9. Guha Mazumder DN, Dasgupta J, Santra A, Pal A, Ghosh A, Sarkar S, Chattopathaya N, Chakraborty D. Non cancer effects of chronic arsenicosis with special reference to liver damage. In: Arsenic: Exposure and Health Effects. Cabernathy R, Calderon W, Chappel W, eds., New York: Chapman & Hall, 1997:112-123.
10. Angle CR. Organ-specific therapeutic intervention. In: Metal Toxicology. Waalkes M, Goyer R, Klaassen C, eds., San Diego, California: Academic Press, 1995:71-110.
11. Kreppel H, Paepcke U, Thiermann H, et al. Therapeutic efficacy of new dimercaptosuccinic acid (DMSA) analogues in acute arsenic trioxide poisoning in mice. Arch Toxicol 1993;67:580-585.
12. Flora SJ, Dube SN, Arora U, Kannan GM, Shukla MK, Malhotra PR. Therapeutic potential of meso 2,3-dimercaptosuccinicacid or 2,3-dimercaptopropane 1-sulfonate in chronic arsenic intoxication in rats. BioMetals 1995;8:111-116.
13. Shum S, Whitehead J, Vanghn L, Shum S, Hale T. Chelation of organoarsenate with dimercaptosuccinic acid. Vet Hum Toxicol 1995;37:239-242.
14. Thianprasit M. Chronic cutaneous arsenism treated with aromatic retinoid. J Med Ass Thai 1984;67: 93-100.
15. Das D, Chatterjee A, Mandai BK, et al. Arsenic in ground water in six districts of West Bengal, India. The biggest arsenic calamity in the world, Part 2. Arsenic concentration in drinking water, hair, nails, urine, skin-scale and liver tissue (biopsy) of the affected people. Analyst 1995;120:917-924.
16. Peters RA, Stocken LA, Thompson RH. British Anti-Lewisite (BAL). Nature 1945;156:616-619.
17. Petrunkin VE. Synthesis and properties of dimercapto derivatives of alkylsulfonic acid. Ukr Khem Zh 1956;22:603-607.
18. Liang YI, Chu CC, Tsen YL, Ting KS. Studies on antibilharzial drugs VI. The antidotal effects of sodium dimercaptosuccinate and BAL-glucoside agonist tartar emetic. Acta Physiol Sin 1957;21:24-32.
19. Inns RH, Rice P, Bright JE, Marrs TC. Evaluation of the efficacy of dimercapto chelating agents for the treatment of systemic organic arsenic poisoning in rabbits. Hum Exp Toxicol 1990;9:215-220.
20. Inns RH, Rice P. Efficacy of dimercapto chelating agents for the treatment of poisoning by percutaneously applied dichloro(2-chlorovinyl) arsene in rabbits. Hum Exp Toxicol 1993;12:241-246.
21. 3 poisoning in mice. Arch Toxicol 1990;64:387-392.
22. 3. Arch Toxicol 1991;65:235-238.
23. Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, et al. Mobilization of heavy metals by newer, therapeutically useful chelating agents. Toxicology 1995; 97:23-38.
24. Angle C. Treatment recommendation for arsenic-poisoned children and adults in West Bengal. Post conference report of the International Conference on Arsenic in Ground Water: Cases Effect and Remedy. Jadavur University, Calcutta, 1995:13.
25. Lenz K, Hruby K, Druml W, et al. 2,3-dimercaptosuccinic acid in human arsenic poisoning. Arch Toxicol 1981;47:241-243.
26. Kew J, Morris C, Aihie A, Fysh R, Jones S, Brooks D. Arsenic and mercury intoxication due to Indian ethnic remedies. BMJ 1993;306:506-507.